GlassScriptPhysician profile
Shuvro Roy
NPI 1174054753
$45,694.98
in general payments reported to CMS, 2019-2025
13 companies · $25K in 2025
The $25K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $188 · 2022: $15.15 · 2023: $3,821 · 2024: $17K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $5,289 · Travel and Lodging: $3,718 · Honoraria: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,660.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,575.00 |
| Food and Beverage | $5,288.97 |
| Travel and Lodging | $3,718.20 |
| Honoraria | $2,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $27,093.15 | 2024-2025 | Uplizna |
| Genentech USA, INC. | $9,263.32 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Horizon Therapeutics Plc | $3,398.90 | 2023 | Uplizna |
| Alexion Pharmaceuticals, INC. | $3,384.87 | 2023-2025 | Ultomiris, Soliris |
| Tg Therapeutics, INC. | $1,483.49 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $628.03 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $161.54 | 2024-2025 | |
| Genentech, INC. | $125.67 | 2024 | Ocrevus |
| Emd Serono, INC. | $65.62 | 2024 | |
| Csl Behring | $25.33 | 2021 | |
| Biogen, INC. | $25.00 | 2025 | Tysabri, Vumerity |
| Kyowa Kirin, INC. | $24.91 | 2021 | |
| Abbvie INC. | $15.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuvro Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.